An Open-Label, Single-Arm, Multicenter
Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen, NCT03173092
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
The purpose of this study is to determine the progression-free survival (PFS) at 2 years for multiple myeloma (MM) participants previously receiving a bortezomib-based induction regimen to ixazomib in combination with lenalidomide and dexamethasone (IRD).
MORE DETAILS ON THIS MULTIPLE MYELOMA TRIAL
17081 / NCT03173092 / Open 10-12-2017
TRIAL AVAILABLE AT THIS LOCATION
All RMCC Locations